Teva Reports Positive Results for Celiac Disease Antibody Drug
Teva Pharmaceutical Industries announced positive results from a Phase 2 clinical trial for its investigational antibody treatment aimed at patients with celiac disease. The drug, TEV-003, demonstrated significant improvements in reducing gluten-induced immune responses and alleviating symptoms in participants.
The trial, which involved a cohort of adult patients with diagnosed celiac disease, evaluated the efficacy and safety of TEV-003 when administered alongside a gluten-free diet. Preliminary data indicated that the antibody helped to mitigate the inflammatory cascade triggered by gluten ingestion, leading to a reduction in intestinal damage and a decrease in reported gastrointestinal distress.
Teva stated that these findings represent a promising step forward in developing a novel therapeutic option for celiac disease, a chronic autoimmune disorder affecting millions worldwide. The company plans to advance the drug candidate into further clinical development, including Phase 3 trials, based on these encouraging outcomes. Further details on the trial's methodology and specific results are expected to be presented at an upcoming medical conference.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
